Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefGoogle ScholarPubMed

Yancik, R.Population aging and cancer: a cross-national concern. Cancer J. 2005;11:437–441.CrossRefGoogle ScholarPubMed

Baudard, M, Marie, JP, Cadiou, M. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol. 1994;86:82–91.CrossRefGoogle ScholarPubMed

Taylor, PR, Reid, MM, Stark, AN. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia. 1995;9:231–237.Google ScholarPubMed

Pinto, A, Zagonel, V, Ferrara, F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol. 2001;39:275–287.CrossRefGoogle ScholarPubMed

Menzin, J, Lang, K, Earle, CC. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Int Med. 2002;162:1597–1603.CrossRefGoogle ScholarPubMed

Bowen, DT.Etiology of acute myeloid leukemia in the elderly. Semin Hematol. 2006;43:82–88.CrossRefGoogle ScholarPubMed

Fialkow, PJ, Singer, JW, Raskind, WH. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317:468–473.CrossRefGoogle ScholarPubMed

Goasguen, JE, Matsuo, T, Cox, C. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6:520–525.Google Scholar

Larson, RA.Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia. 1996;10(suppl 1):23–25.Google ScholarPubMed

Garrido, SM, Cooper, JJ, Appelbaum, FR. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res. 2001;25:23–32.CrossRefGoogle ScholarPubMed

Kamminga, LM, Haan, G. Cellular memory and hematopoietic stem cell aging. Stem Cells. 2006;24:1143–1149.CrossRefGoogle ScholarPubMed

Liang, Y, Zant, G, Szilvassy, SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood. 2005;106:1479–1487.CrossRefGoogle ScholarPubMed

Rossi, DJ, Bryder, D, Zahn, JM. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA. 2005;102:9194–9199.CrossRefGoogle ScholarPubMed

Plesa, C, Chelghoum, Y, Plesa, A. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer. 2008;112:572–580.CrossRefGoogle ScholarPubMed

Grimwade, D, Walker, H, Oliver, F. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333.Google ScholarPubMed

Grimwade, D, Walker, H, Harrison, G. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320.CrossRefGoogle ScholarPubMed

Cancer and Leukemia Group, B, Farag, SS, Archer, KJ. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63–73.Google Scholar

Drenou, B, Fardel, O, Amiot, L. Detection of P glycoprotein activity on normal and leukemic CD34+ cells. Leuk Res. 1993;17:1031–1035.CrossRefGoogle ScholarPubMed

Leith, CP, Kopecky, KJ, Chen, IM. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086–1099.Google ScholarPubMed

Smyth, MJ, Krasovskis, E, Sutton, VR. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA. 1998;95:7024–7029.CrossRefGoogle ScholarPubMed

Baer, MR, George, SL, Dodge, RK. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100:1224–1232.Google ScholarPubMed

Daenen, S, Holt, B, Verhoef, GEG. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. Leuk Res. 2004;28:1057–1067.CrossRefGoogle ScholarPubMed

List, AF, Kopecky, KJ, Willman, CL. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–3220.CrossRefGoogle ScholarPubMed

Solary, E, Drenou, B, Campos, L. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood. 2003;102:1202–1210.CrossRefGoogle ScholarPubMed

Stirewalt, DL, Kopecky, KJ, Meshinchi, S. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–3595.CrossRefGoogle ScholarPubMed

Yanada, M, Matsuo, K, Suzuki, T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19:1345–1349.CrossRefGoogle ScholarPubMed

Scholl, S, Theuer, C, Scheble, V. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol. 2008;80:208–215.CrossRefGoogle ScholarPubMed

Rao, AV, Valk, PJM, Metzeler, KH. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. Journal of Clinical Oncology 2009;27:5580–5586.CrossRefGoogle ScholarPubMed

Fanci, R, Leoni, F, Longo, G. Nosocomial infections in acute leukemia: comparison between younger and elderly patients. New Microbiol. 2008;31:89–96.Google ScholarPubMed

Appelbaum, FR, Gundacker, H, Head, DR. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.CrossRefGoogle ScholarPubMed

Sekeres, MA, Stone, RM, Zahrieh, D. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18:809–816.CrossRefGoogle ScholarPubMed

Alibhai, SMH, Leach, M, Kermalli, H. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol. 2007;64:19–30.CrossRefGoogle ScholarPubMed

Meyers, CA, Albitar, M, Estey, E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–793.CrossRefGoogle ScholarPubMed

Alibhai, SMH, Leach, M, Kowgier, ME. Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status. Leukemia. 2007;21:845–848.CrossRefGoogle ScholarPubMed

Lowenberg, B, Zittoun, R, Kerkhofs, H. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268–1274.CrossRefGoogle ScholarPubMed

Bouabdallah, R, Lefrere, F, Rose, C. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. Leukemia. 1999;13:1491–1496.CrossRefGoogle ScholarPubMed

Ruutu, T, Almqvist, A, Hallman, H. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia. 1994;8:11–15.Google ScholarPubMed

Burnett, AK, Milligan, D, Prentice, AG. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124.CrossRefGoogle Scholar

Yates, J, Glidewell, O, Wiernik, P. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60:454–462.Google ScholarPubMed

Rai, KR, Holland, JF, Glidewell, OJ. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58:1203–1212.Google ScholarPubMed

Mayer, RJ, Davis, RB, Schiffer, CA. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.CrossRefGoogle ScholarPubMed

Abou-Jawde, RM, Sobecks, R, Pohlman, B. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia [see comment]. Leuk Lymphoma. 2006;47:689–695.CrossRefGoogle Scholar

Dowell, JA, Korth-Bradley, J, Liu, H. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41:1206–1214CrossRefGoogle ScholarPubMed

Larson, RA, Sievers, EL, Stadtmauer, EA. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442–1452.CrossRefGoogle ScholarPubMed

Wadleigh, M, Richardson, PG, Zahrieh, D. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation [see comment]. Blood. 2003;102:1578–1582.CrossRefGoogle Scholar

Nabhan, C, Rundhaugen, LM, Riley, MB. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res. 2005;29:53–57.CrossRefGoogle ScholarPubMed

Rao, AV, Rizzieri, DA, Gockerman, JP. Dose dense, high intensity therapy in newly diagnosed elderly patients with acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg) and high dose cytarabine (Hi-DAC). Paper presented at: American Society of Hematology Annual Meeting; December 10–13, 2005; Atlanta, GA.

Bertz, H, Potthoff, K, Finke, J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480–1484.CrossRefGoogle ScholarPubMed

Scott, BL, Sandmaier, BM, Storer, B. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135.CrossRefGoogle ScholarPubMed

Archimbaud, E, Jehn, U, Thomas, X. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia. 1999;13:843–849.CrossRefGoogle Scholar

Giles, F, Rizzieri, D, Karp, J. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007;25:25–31.CrossRefGoogle ScholarPubMed

Schiller, GJ, DeAngelo, D, Vey, N. A phase II study of VNP40101M in elderly patients (pts) with de novo poor risk acute myelogenous leukemia (AML) [abstract 7026]. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 30–June 3, 2008; Chicago, IL.

DeAngelo, DOBS, Vey, N. A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 30–June 3, 2008; Chicago, IL.

Kantarjian, HM, Gandhi, V, Kozuch, P. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21:1167–1173.CrossRefGoogle ScholarPubMed

Erba, HP, KantarjianD,KH D,KH, Claxton, D. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 30–June 3, 2008; Chicago, IL.

Faderl, S, Verstovsek, S, Cortes, J. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006;108:45–51.CrossRefGoogle ScholarPubMed

Faderl, S, Ferrajoli, A, Wierda, W. Clofarabine combinations as acute myeloid leukemia salvage therapy [see comment]. Cancer. 2008;113:2090–2096.CrossRefGoogle Scholar

Giles, FJ, Cortes, JE, Baker, SD. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001;19:762–771.CrossRefGoogle ScholarPubMed

Giles, FJ, Faderl, S, Thomas, DA. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003;21:1050–1056.CrossRefGoogle ScholarPubMed

Plunkett, W, Faderl, S, Cortes, J. Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes. J Clin Oncol. 2007;25(18 suppl):7063.Google Scholar

End, DW, Smets, G, Todd, AV. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131–137.Google ScholarPubMed

Harousseau, J-L, Lancet, JE, Reiffers, J. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007;109:5151–5156.CrossRefGoogle ScholarPubMed

Harousseau, J-L, Jedrzejczak, WW, Martinelli, G. A randomized phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older. Paper presented at: American Society of Hematology Annual Meeting; December 8–11, 2007; Atlanta, GA.

Nakao, M, Yokota, S, Iwai, T. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911–1918.Google ScholarPubMed

Smith, BD, Levis, M, Beran, M. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669–3676.CrossRefGoogle ScholarPubMed

Knapper, S, Burnett, AK, Littlewood, T. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262–3270.CrossRefGoogle Scholar

Altucci, L, Clarke, N, Nebbioso, A. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol. 2005;37:1752–1762.CrossRefGoogle ScholarPubMed

Kosugi, H, Towatari, M, Hatano, S. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 1999;13:1316–1324.CrossRefGoogle ScholarPubMed

Gojo, I, Jiemjit, A, Trepel, JB. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109:2781–2790.Google ScholarPubMed

Braiteh, F, Soriano, AO, Garcia-Manero, G. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008;14:6296–6301.CrossRefGoogle ScholarPubMed

Luca Maurillo, AS, Genuardi, M, Spagnoli, A. 5-Azacytidine for the treatment of acute myeloid leukemia: a retrospective, multicenter study of 55 patients [abstract 1947]. Paper presented at: Annual Meeting of the American Society of Hematology; Nov. 16, 2008; San Francisco, CA.

Cashen, AF, O';Donnell, MR, Larsen, JS. Preliminary results of a multicenter phase II trial of 5-day decitabine as front-line therapy for elderly patients with acute myeloid leukemia (AML) [abstract 560]. Paper presented at: Annual Meeting of the American Society of Hematology; Nov. 16, 2008; San Francisco, CA.

Marcucci, G, Stock, W, Dai, G. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005;23:3404–3411.CrossRefGoogle ScholarPubMed

Marcucci, G, Moser, B, Blum, W. A phase III randomized trial of intensive induction and consolidation chemotherapy +/– oblimersen, a proapoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients > 60 years old. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1–5, 2007; Chicago, IL.

Moore, J, Seiter, K, Kolitz, J. A phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006;30:777–783.CrossRefGoogle ScholarPubMed

Padro, T, Bieker, R, Ruiz, S. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302–1310.CrossRefGoogle ScholarPubMed

Dias, S, Shmelkov, SV, Lam, G. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2002;99:2532–2540.CrossRefGoogle ScholarPubMed

Karp, JE, Gojo, I, Pili, R. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004;10:3577–3585.CrossRefGoogle ScholarPubMed

Heidel, F, Cortes, J, Rucker, FG. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and imatinib. Cancer. 2007;109:907–914.CrossRefGoogle ScholarPubMed

Park, S, Chapuis, N, Bardet, V. PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 2008;22:1698–1706.CrossRefGoogle ScholarPubMed

Kantarjian, H, O';Brien, S, Cortes, J. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.CrossRefGoogle ScholarPubMed

Budel, LM, Dong, F, Lowenberg, B. Hematopoietic growth factor receptors: structure variations and alternatives of receptor complex formation in normal hematopoiesis and in hematopoietic disorders. Leukemia. 1995;9:553–561.Google ScholarPubMed

Lowenberg, B, Touw, IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 1993;81:281–292.Google ScholarPubMed

Lowenberg, B, Delwel, R, Touw, I. Hematopoietic growth factors and in vitro growth of human acute myeloblastic leukemia. Crit Rev Oncol Hematol. 1990;10:1–8.CrossRefGoogle ScholarPubMed

Lowenberg, B, Suciu, S, Archimbaud, E. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90:2952–2961.Google ScholarPubMed

Rowe, JM, Andersen, JW, Mazza, JJ. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–462.Google Scholar

Rowe, JM, Neuberg, D, Friedenberg, W. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479–485.CrossRefGoogle ScholarPubMed

Stone, RM, Berg, DT, George, SL. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671–1677.CrossRefGoogle ScholarPubMed

Witz, F, Sadoun, A, Perrin, MC. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998;91:2722–2730.Google Scholar

Dombret, H, Chastang, C, Fenaux, P. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332:1678–1683.CrossRefGoogle ScholarPubMed

Amadori, S, Suciu, S, Jehn, U. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27–34.CrossRefGoogle ScholarPubMed

Bedard, PL, Piccart-Gebhart, MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer. 2008;4(suppl):S157–S165.CrossRefGoogle Scholar

Wilson, CS, Davidson, GS, Martin, SB. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108:685–696.CrossRefGoogle ScholarPubMed

Grimwade, D, Moorman, A, Hills, R. Impact of karyotype on treatment outcome in acute myeloid leukemia. Ann Hematol. 2004;83(suppl 1):S45–S48.Google ScholarPubMed

Heuvel-Eibrink, MM, Holt, B, Burnett, AK. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329–337.CrossRefGoogle ScholarPubMed